New pharmaconutraceutical Chondroguard®TRIO for the prevention of musculoskeletal diseases and nutritional support for patients with osteoarthritis and nonspecific back pain: an assessment of clinical options. Resolution of the Multidisciplinary Expert Council-Reference-Cited by-同舟云学术

New pharmaconutraceutical Chondroguard®TRIO for the prevention of musculoskeletal diseases and nutritional support for patients with osteoarthritis and nonspecific back pain: an assessment of clinical options. Resolution of the Multidisciplinary Expert Council

Published:2023-05-01 Issue:2 Volume:15 Page:134-146
ISSN:2310-1342
Container-title:Neurology, Neuropsychiatry, Psychosomatics
language:
Short-container-title:RJTAO

Author:

Danilov Al. B.¹,Lila A. M.²,Majidova Yo. N.³,Gromova O. A.⁴,Tkacheva O. N.⁵,Sarvilina I. V.⁶,Kochish A. Yu.⁷,Nazarenko A. G.⁸,Zagorodniy N. V.⁸,Minasov T. B.⁹,Alekseeva L. I.¹⁰,Taskina E. A.¹⁰,Kotovskaya Yu. V.⁵,Dudinskaya E. N.⁵,Rozanov A. V.⁵,Solovieva E. Yu.¹¹,Shavlovskaya O. A.¹²,Sharov M. N.¹³,Kamchatnov P. R.¹¹,Rachin A. P.¹⁴,Barantsevich E. R.¹⁵,Iskra D. A.¹⁶,Yakupov E. Z.¹⁷,Devlikamova F. I.¹⁸,Barulin A. E.¹⁹,Nesterova M. V.²⁰,Sakovets T. G.²¹,Barinov A. N.²²,Dolgova I. N.²³,Zabolotskikh N. V.²⁴,Zonova E. V.²⁵,Shchepankevich L. A.²⁵,Parfenov V. A.¹,Dzhurabekova A. T.²⁶,Khakimova S. Z.²⁶

Affiliation:

1. I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

2. V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education

3. Tashkent Pediatric Medical Institute

4. Federal Research Center “Computer Science and Control”, Russian Academy of Sciences

5. Russian Clinical and Research Center of Gerontology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

6. Medical Center Novomeditsina LLC

7. Russian Scientific Research Institute of Traumatology and Orthopedics named after R.R. Vreden

8. N.N. Priorov National Medical Research Center of Traumatology and Orthopedics

9. Bashkir State Medical University, Ministry of Health of Russia

10. V.A. Nasonova Research Institute of Rheumatology

11. N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

12. International University of Restorative Medicine

13. A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

14. National Association of Experts in Comorbid Neurology

15. Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

16. Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia

17. Neuroclinic of Professor Yakupov

18. Kazan State Medical Academy, branch of Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

19. Volgograd State Medical University, Ministry of Health of Russia

20. Ural State Medical University, Ministry of Health of Russia

21. Kazan State Medical University, Ministry of Health of Russia

22. Medical Academy of JSC “MEDSI” Group of Companies”

23. Stavropol State Medical University, Ministry of Health of Russia

24. Kuban State Medical University, Ministry of Health of Russia

25. Novosibirsk State Medical University, Ministry of Health of Russia

26. Samarkand State Medical University

Abstract

In recent decades, there has been an increase in the prevalence and medical and social burden of osteoarthritis (OA) and nonspecific back pain in all countries of the world. The First Multidisciplinary Bilateral Russia-Uzbekistan Expert Council presented innovations in the prognosing, personalized prevention and adjuvant therapy of degenerative-dystrophic diseases of the joints and spine, the evidence base for the effectiveness and safety of the use of drugs that modify the course of OA (Disease-modifying osteoarthritis drugs, DMOADs): chondroitin sulfate, glucosamine sulfate, undenatured type II collagen for adjuvant pharmaconutraceutical support – prevention and adjuvant therapy (treatment) of OA and nonspecific lumbosacral pain. The expert counsil resolution presents an optimized algorithm for the management, prevention and adjuvant therapy of OA and non-specific back pain, maintaining the function of healthy joints after intense physical activity with the inclusion of the drug Chondroguard solution for intra-articular and intramuscular administration (INN – chondroitin sulfate) and a new pharmaconutraceutical from the DMOADs group – TRIO trademark Chondroguard® (Chondroguard®TRIO).

Publisher

IMA Press, LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Clinical Psychology

Reference69 articles.

1. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.

2. Leifer V, Katz J, Losina E. The burden of OAhealth services and economics. Osteoarthritis Cartilage. 2022;30:10-6. doi: 10.1016/j.joca.2021.05.007

3. Felson D. The epidemiology of knee osteoarthritis: Results from the Framingham Osteoarthritis Study. Semin Arthritis Rheum. 1990;20:42-50. doi: 10.1016/0049-0172(90)90046-i

4. Balabanova RM, Dubinina TV. Five-year (2013–2017) trends in the incidence and prevalence of musculoskeletal system diseases among the adult population of Russia. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(4):11-7. doi: 10.14412/ 1996-7012-2019-4-11-17 (In Russ.).

5. Galushko EA, Nasonov EL. Prevalence of rheumatic diseases in Russia. Al’manakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2018;46(1):32-9. doi: 10.18786/2072-0505-2018-46-1-32-39 (In Russ.).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On the immunotropic effects of a new combined pharmaconutraceutical preparation in osteoarthritis;Modern Rheumatology Journal;2024-08-21

2. Admitting a patient with musculoskeletal pain following COVID-19 disease;Neurology, Neuropsychiatry, Psychosomatics;2023-12-17

3. DMOADs and DMARDs in the treatment of patients with joint and spine diseases;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2023-12-12

4. Pharmaconutraceutical Chondroguard®TRIO – chondroprotector with immunomodulatory activity;Neurology, Neuropsychiatry, Psychosomatics;2023-08-15